JP2018509175A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018509175A5 JP2018509175A5 JP2017551580A JP2017551580A JP2018509175A5 JP 2018509175 A5 JP2018509175 A5 JP 2018509175A5 JP 2017551580 A JP2017551580 A JP 2017551580A JP 2017551580 A JP2017551580 A JP 2017551580A JP 2018509175 A5 JP2018509175 A5 JP 2018509175A5
- Authority
- JP
- Japan
- Prior art keywords
- bispecific tetravalent
- tetravalent antibody
- cancer
- pharmaceutical composition
- binding specificity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 13
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 13
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 13
- 125000003275 alpha amino acid group Chemical group 0.000 claims 11
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims 9
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 8
- 229940124597 therapeutic agent Drugs 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 7
- 229940127089 cytotoxic agent Drugs 0.000 claims 3
- 239000013604 expression vector Substances 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- HKZAAJSTFUZYTO-LURJTMIESA-N (2s)-2-[[2-[[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]acetyl]amino]acetyl]amino]-3-hydroxypropanoic acid Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O HKZAAJSTFUZYTO-LURJTMIESA-N 0.000 claims 2
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 229960004891 lapatinib Drugs 0.000 claims 2
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims 2
- 229960003881 letrozole Drugs 0.000 claims 2
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- -1 trastuzumab Chemical compound 0.000 claims 2
- CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 claims 1
- 102100026882 Alpha-synuclein Human genes 0.000 claims 1
- 206010061424 Anal cancer Diseases 0.000 claims 1
- 208000007860 Anus Neoplasms Diseases 0.000 claims 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 claims 1
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 102100027207 CD27 antigen Human genes 0.000 claims 1
- 101150013553 CD40 gene Proteins 0.000 claims 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 1
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 claims 1
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims 1
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims 1
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims 1
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims 1
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 claims 1
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims 1
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims 1
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 1
- 101000955999 Homo sapiens V-set domain-containing T-cell activation inhibitor 1 Proteins 0.000 claims 1
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 claims 1
- 239000005536 L01XE08 - Nilotinib Substances 0.000 claims 1
- 102000017578 LAG3 Human genes 0.000 claims 1
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims 1
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims 1
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 1
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 claims 1
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 229960003437 aminoglutethimide Drugs 0.000 claims 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 claims 1
- 229960002932 anastrozole Drugs 0.000 claims 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims 1
- 201000011165 anus cancer Diseases 0.000 claims 1
- 230000004071 biological effect Effects 0.000 claims 1
- 230000005907 cancer growth Effects 0.000 claims 1
- 229960004117 capecitabine Drugs 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 229910052802 copper Inorganic materials 0.000 claims 1
- 239000010949 copper Substances 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 229960002448 dasatinib Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229960001433 erlotinib Drugs 0.000 claims 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 239000000328 estrogen antagonist Substances 0.000 claims 1
- 210000003527 eukaryotic cell Anatomy 0.000 claims 1
- 229960000255 exemestane Drugs 0.000 claims 1
- 229950011548 fadrozole Drugs 0.000 claims 1
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims 1
- 229960004421 formestane Drugs 0.000 claims 1
- OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 claims 1
- 229960002258 fulvestrant Drugs 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 229960002584 gefitinib Drugs 0.000 claims 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 229960002411 imatinib Drugs 0.000 claims 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 150000002596 lactones Chemical class 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 229960001346 nilotinib Drugs 0.000 claims 1
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 210000001236 prokaryotic cell Anatomy 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 229960003787 sorafenib Drugs 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 229960001796 sunitinib Drugs 0.000 claims 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims 1
- 229960001603 tamoxifen Drugs 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021068859A JP7335290B2 (ja) | 2014-12-22 | 2021-04-15 | 二重特異性四価抗体並びにその製作及び使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462095348P | 2014-12-22 | 2014-12-22 | |
| US62/095,348 | 2014-12-22 | ||
| PCT/US2015/066951 WO2016106157A1 (en) | 2014-12-22 | 2015-12-19 | Bispecific tetravalent antibodies and methods of makiing and using thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021068859A Division JP7335290B2 (ja) | 2014-12-22 | 2021-04-15 | 二重特異性四価抗体並びにその製作及び使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018509175A JP2018509175A (ja) | 2018-04-05 |
| JP2018509175A5 true JP2018509175A5 (OSRAM) | 2019-02-07 |
| JP6947639B2 JP6947639B2 (ja) | 2021-10-13 |
Family
ID=56151464
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017551580A Active JP6947639B2 (ja) | 2014-12-22 | 2015-12-19 | 二重特異性四価抗体並びにその製作及び使用方法 |
| JP2021068859A Active JP7335290B2 (ja) | 2014-12-22 | 2021-04-15 | 二重特異性四価抗体並びにその製作及び使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021068859A Active JP7335290B2 (ja) | 2014-12-22 | 2021-04-15 | 二重特異性四価抗体並びにその製作及び使用方法 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US10919977B2 (OSRAM) |
| EP (3) | EP4491195A3 (OSRAM) |
| JP (2) | JP6947639B2 (OSRAM) |
| KR (4) | KR102590385B1 (OSRAM) |
| CN (11) | CN106659779B (OSRAM) |
| AU (1) | AU2015369831B2 (OSRAM) |
| CA (2) | CA2969867C (OSRAM) |
| DK (1) | DK3237005T3 (OSRAM) |
| ES (2) | ES2995733T3 (OSRAM) |
| FI (1) | FI3237005T3 (OSRAM) |
| HR (1) | HRP20241502T1 (OSRAM) |
| HU (1) | HUE069256T2 (OSRAM) |
| IL (3) | IL286835B2 (OSRAM) |
| LT (1) | LT3237005T (OSRAM) |
| NZ (1) | NZ732628A (OSRAM) |
| PL (1) | PL3237005T3 (OSRAM) |
| PT (1) | PT3237005T (OSRAM) |
| RS (1) | RS66070B1 (OSRAM) |
| SG (1) | SG11201704741PA (OSRAM) |
| SI (1) | SI3237005T1 (OSRAM) |
| SM (1) | SMT202400477T1 (OSRAM) |
| WO (2) | WO2016106158A1 (OSRAM) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2969867C (en) * | 2014-12-22 | 2022-01-25 | Systimmune, Inc. | Bispecific tetravalent antibodies and methods of making and using thereof |
| US12428483B2 (en) | 2014-12-22 | 2025-09-30 | Systimmune, Inc. | Bispecific tetravalent antibodies and methods of making and using thereof |
| JP2018503399A (ja) * | 2015-01-14 | 2018-02-08 | コンパス セラピューティクス リミテッド ライアビリティ カンパニー | 多特異性免疫調節抗原結合構築物 |
| CN106632681B (zh) * | 2016-10-11 | 2017-11-14 | 北京东方百泰生物科技有限公司 | 抗egfr和抗cd3双特异抗体及其应用 |
| CN108948195B (zh) * | 2017-05-23 | 2022-05-31 | 胡毅 | 一种抗egfr/pd-l1双靶向抗体、其制备方法及用途 |
| JP7323513B2 (ja) * | 2017-06-25 | 2023-08-08 | システィミューン， インク． | 抗４－１ｂｂ抗体とその作製及び使用方法 |
| CA3069238A1 (en) * | 2017-11-02 | 2019-05-09 | Systimmune, Inc. | Bispecific antibodies and methods of making and using thereof |
| US11708410B2 (en) | 2018-01-15 | 2023-07-25 | Nanjing Legend Biotech Co., Ltd. | Antibodies and variants thereof against TIGIT |
| CN107974461A (zh) * | 2018-01-18 | 2018-05-01 | 东北农业大学 | 一种高效表达anti-hEGFR基因的真核表达载体构建方法 |
| CN108220244A (zh) * | 2018-01-18 | 2018-06-29 | 东北农业大学 | 一种含重组人表皮生长因子受体抗体基因的cho细胞株、筛选方法及其生产工艺 |
| KR20200143436A (ko) * | 2018-04-13 | 2020-12-23 | 아피메트 게엠베하 | Nk 세포 결합 항체 융합 구조체 |
| CN112512575B (zh) * | 2018-05-16 | 2024-08-06 | 嘉立医疗科技(广州)有限公司 | 双特异性抗体组合物及其使用方法 |
| EP3833690B1 (en) | 2018-08-08 | 2024-03-27 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Recombinant bifunctional protein targeting cd47 and her2 |
| CN110850068B (zh) * | 2018-08-21 | 2023-08-15 | 上海恒润达生生物科技股份有限公司 | 一种嵌合抗原受体亲和力检测方法 |
| WO2020061376A2 (en) * | 2018-09-19 | 2020-03-26 | Alpine Immune Sciences, Inc. | Methods and uses of variant cd80 fusion proteins and related constructs |
| CN113301919B (zh) * | 2018-11-13 | 2025-01-28 | Jn生物科学有限责任公司 | 激活免疫细胞的双特异性抗体 |
| CN114450306B (zh) * | 2019-07-26 | 2024-04-05 | Abl生物公司 | 抗egfr/抗4-1bb双特异性抗体及其用途 |
| AU2020327000A1 (en) | 2019-08-08 | 2022-03-31 | Regeneron Pharmaceuticals, Inc. | Novel antigen binding molecule formats |
| CA3170338A1 (en) * | 2020-02-19 | 2021-08-26 | Denali Therapeutics Inc. | Engineered anti-her2 bispecific proteins |
| TWI874613B (zh) * | 2020-03-17 | 2025-03-01 | 美商西雅圖免疫公司 | 微型導引和導航控制(miniGNC)類抗體蛋白及其製造和使用方法 |
| CN111548424A (zh) * | 2020-06-05 | 2020-08-18 | 上海科弈药业科技有限公司 | 一种靶向egfr与cd47的多功能融合蛋白及其应用 |
| WO2022061255A1 (en) * | 2020-09-21 | 2022-03-24 | Systimmune, Inc. | Specificity enchanced bispecific antibody (seba) |
| IL311035A (en) * | 2021-08-25 | 2024-04-01 | Systimmune Inc | TETRAVALENT BISPIFIC ANTIBODIES TARGETING EGFR AND HER3 |
| US20250223376A1 (en) * | 2021-09-20 | 2025-07-10 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
| WO2023056485A1 (en) * | 2021-10-03 | 2023-04-06 | Systimmune, Inc. | Methods of treating cancer and the pharmaceutical compositions thereof |
| KR20240101682A (ko) * | 2021-11-15 | 2024-07-02 | 시스트이뮨, 인코포레이티드 | 이중특이 항체-캄프토테신 약물 접합체 및 이의 약학적 용도 |
| WO2023241480A1 (zh) * | 2022-06-13 | 2023-12-21 | 三优生物医药(上海)有限公司 | 抗pd-l1、vegf和egfr三特异性抗体及其应用 |
| AU2023334288A1 (en) * | 2022-08-31 | 2025-03-20 | Systimmune, Inc. | Biepitopic tetravalent antibody targeting egfr |
| CN116063564A (zh) * | 2022-10-08 | 2023-05-05 | 盛禾(中国)生物制药有限公司 | 一种纯化融合蛋白的方法 |
| WO2024168588A1 (en) * | 2023-02-15 | 2024-08-22 | Zhejiang Shimai Pharmaceutical Co., Ltd. | Egfr and lag3 dual targeted bispecific antibody and uses thereof |
| TW202502823A (zh) * | 2023-07-07 | 2025-01-16 | 大陸商四川科倫博泰生物醫藥股份有限公司 | Ｅｇｆｒ／ｃ－ｍｅｔ雙特異性結合蛋白及其用途 |
| WO2025026282A1 (en) * | 2023-07-29 | 2025-02-06 | Shanghai Kaijin Biotechnology, Ltd | Modified type e multi-specific antibodies |
| WO2025117871A1 (en) * | 2023-11-29 | 2025-06-05 | Systimmune, Inc. | Bispecific tetravalent antibody targeting her2 and her3 |
| WO2025140662A1 (en) * | 2023-12-29 | 2025-07-03 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Anti-egfr/her3 antibodies and uses thereof |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2200753B (en) | 1986-12-23 | 1991-01-23 | Brookes & Gatehouse | Speed measurement device |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| CA2473144C (en) * | 2002-02-05 | 2013-05-28 | Genentech, Inc. | Protein purification |
| US7332585B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The California University | Bispecific single chain Fv antibody molecules and methods of use thereof |
| ZA200702427B (en) * | 2004-09-17 | 2008-12-31 | Domantis Ltd | Compositions monovalent for CD40L binding and methods of use |
| MX2008015852A (es) * | 2006-06-14 | 2009-02-23 | Imclone Systems Inc | Formulaciones liofilizadas de anticuerpos anti-egfr. |
| AU2007353412A1 (en) * | 2006-11-21 | 2008-11-20 | Fox Chase Cancer Center | Anti-EGFR family antibodies, bispecific anti-EGFR family antibodies and methods of use thereof |
| MA33198B1 (fr) * | 2009-03-20 | 2012-04-02 | Genentech Inc | Anticorps anti-her di-spécifiques |
| JP2012521768A (ja) | 2009-03-27 | 2012-09-20 | ジモジェネティクス・インコーポレイテッド | 抗体−受容体の組み合わせを含む多特異的結合性タンパク質を用いるための組成物および方法 |
| CN102369215B (zh) * | 2009-04-02 | 2015-01-21 | 罗切格利卡特公司 | 包含全长抗体和单链Fab片段的多特异性抗体 |
| MX2011010166A (es) * | 2009-04-07 | 2011-10-11 | Roche Glycart Ag | Anticuerpos biespecificos anti-erbb-3/anti-c-met. |
| SG178602A1 (en) * | 2009-09-01 | 2012-04-27 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| JP5960598B2 (ja) * | 2009-11-04 | 2016-08-02 | アフィボディ・アーベー | Ｈｅｒ３結合ポリペプチド |
| EP2621532A1 (en) * | 2010-09-30 | 2013-08-07 | Merck Sharp & Dohme Corp. | Generation, characterization and uses thereof of anti-her3 antibodies |
| CA2817448C (en) * | 2010-12-23 | 2019-01-22 | F. Hoffmann-La Roche Ag | Binding agent |
| TWI838039B (zh) * | 2011-03-28 | 2024-04-01 | 法商賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
| US20140170148A1 (en) * | 2011-04-20 | 2014-06-19 | Genmab A/S | Bispecific antibodies against her2 |
| JP6177231B2 (ja) * | 2011-04-20 | 2017-08-09 | ゲンマブ エー／エス | Ｈｅｒ２に対する二重特異性抗体 |
| AU2012248470B2 (en) * | 2011-04-25 | 2016-10-27 | Daiichi Sankyo Company, Limited | Anti-B7-H3 antibody |
| CN102250246A (zh) * | 2011-06-10 | 2011-11-23 | 常州亚当生物技术有限公司 | 抗VEGF/PDGFRβ双特异性抗体及其应用 |
| CN102250247B (zh) | 2011-06-15 | 2013-06-19 | 常州亚当生物技术有限公司 | 一种抗vegf/ang2双特异性抗体及其应用 |
| CN104203981A (zh) * | 2011-12-19 | 2014-12-10 | 合成免疫股份有限公司 | 双特异性抗体分子 |
| US8961971B2 (en) * | 2011-12-22 | 2015-02-24 | Development Center For Biotechnology | Bispecific T-cell activator antibody |
| MX2014011500A (es) * | 2012-03-27 | 2014-12-05 | Genentech Inc | Diagnosticos y tratamientos relacionados a inhibidores her3. |
| WO2014012082A2 (en) * | 2012-07-13 | 2014-01-16 | Zymeworks Inc. | Multivalent heteromultimer scaffold design an constructs |
| EP2922872B1 (en) * | 2012-11-21 | 2018-10-10 | Janssen Biotech, Inc. | Bispecific egfr/c-met antibodies |
| CN104688740A (zh) * | 2012-12-21 | 2015-06-10 | 百奥泰生物科技(广州)有限公司 | 类美登素衍生物及其制备方法和用途 |
| JP2016514676A (ja) * | 2013-03-15 | 2016-05-23 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | 四価二重特異性抗体 |
| CN104211814A (zh) * | 2013-05-29 | 2014-12-17 | 三星电子株式会社 | 用于消耗靶膜蛋白的组合物 |
| CA2969867C (en) | 2014-12-22 | 2022-01-25 | Systimmune, Inc. | Bispecific tetravalent antibodies and methods of making and using thereof |
-
2015
- 2015-12-19 CA CA2969867A patent/CA2969867C/en active Active
- 2015-12-19 WO PCT/US2015/066952 patent/WO2016106158A1/en not_active Ceased
- 2015-12-19 PT PT158742163T patent/PT3237005T/pt unknown
- 2015-12-19 SI SI201532042T patent/SI3237005T1/sl unknown
- 2015-12-19 AU AU2015369831A patent/AU2015369831B2/en active Active
- 2015-12-19 US US15/119,694 patent/US10919977B2/en active Active
- 2015-12-19 HR HRP20241502TT patent/HRP20241502T1/hr unknown
- 2015-12-19 CN CN201580036408.7A patent/CN106659779B/zh active Active
- 2015-12-19 KR KR1020237021346A patent/KR102590385B1/ko active Active
- 2015-12-19 KR KR1020237034930A patent/KR102823201B1/ko active Active
- 2015-12-19 ES ES15874216T patent/ES2995733T3/es active Active
- 2015-12-19 WO PCT/US2015/066951 patent/WO2016106157A1/en not_active Ceased
- 2015-12-19 DK DK15874216.3T patent/DK3237005T3/da active
- 2015-12-19 CN CN202110471245.2A patent/CN113512123B/zh active Active
- 2015-12-19 KR KR1020177020104A patent/KR102548827B1/ko active Active
- 2015-12-19 JP JP2017551580A patent/JP6947639B2/ja active Active
- 2015-12-19 CN CN201580073430.9A patent/CN107206074B/zh active Active
- 2015-12-19 CN CN202110470781.0A patent/CN113105552B/zh active Active
- 2015-12-19 SG SG11201704741PA patent/SG11201704741PA/en unknown
- 2015-12-19 ES ES15874217T patent/ES2962675T3/es active Active
- 2015-12-19 EP EP24200270.7A patent/EP4491195A3/en active Pending
- 2015-12-19 CN CN202110471082.8A patent/CN113512122B/zh active Active
- 2015-12-19 KR KR1020257020085A patent/KR20250094744A/ko active Pending
- 2015-12-19 IL IL286835A patent/IL286835B2/en unknown
- 2015-12-19 EP EP15874216.3A patent/EP3237005B1/en active Active
- 2015-12-19 SM SM20240477T patent/SMT202400477T1/it unknown
- 2015-12-19 NZ NZ732628A patent/NZ732628A/en unknown
- 2015-12-19 CN CN202110471052.7A patent/CN113512121B/zh active Active
- 2015-12-19 CN CN202311507433.1A patent/CN117467017A/zh active Pending
- 2015-12-19 US US15/538,189 patent/US10717783B2/en active Active
- 2015-12-19 CN CN202110470818.XA patent/CN113512120B/zh active Active
- 2015-12-19 CN CN202110471476.3A patent/CN113150165B/zh active Active
- 2015-12-19 LT LTEPPCT/US2015/066951T patent/LT3237005T/lt unknown
- 2015-12-19 CN CN202110470743.5A patent/CN113105551B/zh active Active
- 2015-12-19 EP EP15874217.1A patent/EP3237006B1/en active Active
- 2015-12-19 FI FIEP15874216.3T patent/FI3237005T3/fi active
- 2015-12-19 PL PL15874216.3T patent/PL3237005T3/pl unknown
- 2015-12-19 HU HUE15874216A patent/HUE069256T2/hu unknown
- 2015-12-19 RS RS20241150A patent/RS66070B1/sr unknown
- 2015-12-19 CA CA3138083A patent/CA3138083A1/en active Pending
- 2015-12-19 IL IL305193A patent/IL305193A/en unknown
- 2015-12-19 CN CN202110471392.XA patent/CN113105553B/zh active Active
-
2017
- 2017-06-11 IL IL252811A patent/IL252811B/en unknown
-
2021
- 2021-04-15 JP JP2021068859A patent/JP7335290B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018509175A5 (OSRAM) | ||
| JP7335290B2 (ja) | 二重特異性四価抗体並びにその製作及び使用方法 | |
| US12384853B2 (en) | Anti-HER2/PD1 bispecific antibody | |
| JP2018503380A5 (OSRAM) | ||
| RU2018106452A (ru) | Поливалетные и полиспецифичные gitr-связывающие слитые белки | |
| JP2019524693A5 (OSRAM) | ||
| RU2014101669A (ru) | Агенты, связывающие белки r-спондины (rspo), и способы их применения | |
| HRP20192098T1 (hr) | Antitijela na glukokortikoidom inducirani receptor faktora nekroze tumora (gitr) i njihove primjene | |
| RU2020120613A (ru) | Антитела, нацеленные на рецептор, связанный с g-белками, и способы их применения | |
| JP2013527762A5 (OSRAM) | ||
| JP2014503189A5 (OSRAM) | ||
| JP7679399B2 (ja) | 抗ｆｌｔ３抗体及び組成物 | |
| JP2021501575A5 (OSRAM) | ||
| JP7418326B2 (ja) | 二重特異性抗体並びにその製造方法及び使用方法 | |
| JP2024520577A (ja) | 抗ｎｋｇ２ａ抗体及び組成物 | |
| WO2025016459A1 (zh) | 一种抗fgfr2/pd-1双特异性抗体 | |
| CN104650228A (zh) | 一种全人源her2抗体、其编码基因及应用 | |
| US12428483B2 (en) | Bispecific tetravalent antibodies and methods of making and using thereof | |
| HK40120554A (en) | Bispecific tetravalent antibodies and methods of makiing and using thereof | |
| RU2024107459A (ru) | Биспецифическое тетравалентное антитело против egfr и her3 | |
| CN104497140A (zh) | 一种全人源her2抗体、其编码基因及应用 | |
| NZ763370B2 (en) | Bispecific antibodies and methods of making and using thereof | |
| HK1233941A1 (en) | Bispecific tetravalent antibodies and methods of making and using thereof | |
| JPWO2021133167A5 (OSRAM) | ||
| RU2020114236A (ru) | Новые биспецифичные полипептидные комплексы против cd3/cd19 |